Roee Arnon1, Irit Rozen-Knisbacher2,3, Tal Yahalomi2, Nir Stanescu2, Yulia Niazov2, Dina Goldberg2, Adi Sharabi-Nov4, Dina Mostovoy2,3. 1. Assuta-Samson Medical Center, Ophthalmology Department, University/Hospital: Ben-Gurion University, Harefuah 7 Street, 7747629, Ashdod, Israel. roee.arnon@gmail.com. 2. Assuta-Samson Medical Center, Ophthalmology Department, University/Hospital: Ben-Gurion University, Harefuah 7 Street, 7747629, Ashdod, Israel. 3. School of Medicine, Ben Gurion University, Beer-Sheva, Israel. 4. Tel Hai Academy, Tel-Hai, Upper Galilee, Israel.
Abstract
PURPOSE: The aim of this study was to compare treatment regimens of tacrolimus and of topical steroids for VKC and suggest a treatment protocol according to our clinical experience. METHODS: This retrospective, nonrandomized case series enrolled 85 patients with VKC. Patients were classified clinically according to severity (mild, moderate, severe) and were treated according to a suggested protocol. Analysis was made according to treatment received: tacrolimus ointment as first line treatment (tacrolimus 1st line), tacrolimus ointment after topical steroid drops treatment (tacrolimus 2nd line) and topical steroid drops or artificial tears alone (topical steroid and tears group). RESULTS: Significant improvements in clinical signs and symptoms were achieved under tacrolimus treatment 14 months in the moderate group and 5 months in the severe group. The longest duration of treatment was for tacrolimus 2nd line group (p = 0.031) and the mean number of visits in the clinic was the highest. The mean number of topical treatments per day was higher in the topical steroid and tears group (2.6 times) than in the two tacrolimus groups (1.3 times for both). The mean time needed to achieve disease remission or relief did not differ between the tacrolimus 1st line and 2nd line groups. CONCLUSION: Tacrolimus treatment is effective and safe for VKC. Tacrolimus as 1st line treatment may be preferred for severe cases, for faster disease remission compared to tacrolimus as 2nd line treatment; and with fewer topical treatments per day compared to topical steroids.
PURPOSE: The aim of this study was to compare treatment regimens of tacrolimus and of topical steroids for VKC and suggest a treatment protocol according to our clinical experience. METHODS: This retrospective, nonrandomized case series enrolled 85 patients with VKC. Patients were classified clinically according to severity (mild, moderate, severe) and were treated according to a suggested protocol. Analysis was made according to treatment received: tacrolimus ointment as first line treatment (tacrolimus 1st line), tacrolimus ointment after topical steroid drops treatment (tacrolimus 2nd line) and topical steroid drops or artificial tears alone (topical steroid and tears group). RESULTS: Significant improvements in clinical signs and symptoms were achieved under tacrolimus treatment 14 months in the moderate group and 5 months in the severe group. The longest duration of treatment was for tacrolimus 2nd line group (p = 0.031) and the mean number of visits in the clinic was the highest. The mean number of topical treatments per day was higher in the topical steroid and tears group (2.6 times) than in the two tacrolimus groups (1.3 times for both). The mean time needed to achieve disease remission or relief did not differ between the tacrolimus 1st line and 2nd line groups. CONCLUSION: Tacrolimus treatment is effective and safe for VKC. Tacrolimus as 1st line treatment may be preferred for severe cases, for faster disease remission compared to tacrolimus as 2nd line treatment; and with fewer topical treatments per day compared to topical steroids.
Authors: Soo Y Kim; Angela J Busch; Tom J Overend; Candice L Schachter; Ina van der Spuy; Catherine Boden; Suelen M Góes; Heather Ja Foulds; Julia Bidonde Journal: Cochrane Database Syst Rev Date: 2019-09-02